Format

Send to

Choose Destination
Am J Trop Med Hyg. 2011 Dec;85(6):1015-24. doi: 10.4269/ajtmh.2011.11-0464.

Review: Malaria chemoprophylaxis for travelers to Latin America.

Author information

1
Malaria Branch, Division of Parasitic Diseases and Malaria, Centers for Disease Prevention and Control, Atlanta, Georgia 30333, USA. LSteinhardt@cdc.gov

Abstract

Because of recent declining malaria transmission in Latin America, some authorities have recommended against chemoprophylaxis for most travelers to this region. However, the predominant parasite species in Latin America, Plasmodium vivax, can form hypnozoites sequestered in the liver, causing malaria relapses. Additionally, new evidence shows the potential severity of vivax infections, warranting continued consideration of prophylaxis for travel to Latin America. Individualized travel risk assessments are recommended and should consider travel locations, type, length, and season, as well as probability of itinerary changes. Travel recommendations might include no precautions, mosquito avoidance only, or mosquito avoidance and chemoprophylaxis. There are a range of good options for chemoprophylaxis in Latin America, including atovaquone-proguanil, doxycycline, mefloquine, and--in selected areas--chloroquine. Primaquine should be strongly considered for nonpregnant, G6PD-nondeficient patients traveling to vivax-endemic areas of Latin America, and it has the added benefit of being the only drug to protect against malaria relapses.

PMID:
22144437
PMCID:
PMC3225145
DOI:
10.4269/ajtmh.2011.11-0464
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Ingenta plc Icon for PubMed Central
Loading ...
Support Center